SCHEMBL627189

SCHEMBL627189

FC1CCN(c2nc(-n3cccn3)nc3ccc(C4CCCCC4)cc23)CC1

nearest known ligand 0.67

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
EGLN1 Q9GZT9 18/20 0.67
ADORA2A P29274 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL626745 0.94 EGLN1 (0.66) EGLN1ADORA2A
SCHEMBL626735 0.94 EGLN1 (0.66) EGLN1ADORA2A
SCHEMBL627894 0.94 EGLN1 (0.66) EGLN1ADORA2A
SCHEMBL16626167 0.92 EGLN1 (0.68) EGLN1
SCHEMBL16626160 0.90 EGLN1 (0.68) EGLN1ADORA2A
SCHEMBL627010 0.88 EGLN1 (0.69) EGLN1ADORA2A
SCHEMBL21802967 0.81 EGLN1 (0.62) EGLN1ADORA2A
SCHEMBL623547 0.80 EGLN1 (1.00) EGLN1
SCHEMBL16626214 0.79 EGLN1 (0.64) EGLN1ADORA2A
SCHEMBL14992368 0.79 EGLN1 (0.64) EGLN1ADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2019-04-02 US disclosed
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2018-05-31 US disclosed
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2017-11-09 US disclosed
US-9573940-B2 4-aminoquinazolinyl-2-yl-1-pyrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2017-02-21 US disclosed
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2015-07-16 US disclosed
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARAMCEUTICA NV (BE) 2014-10-16 US disclosed
US-8796263-B2 4-aminoquinazolin-2-yl-1-pyrrazole-4-carboxylic acid compounds as prolyl hydroxylase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2014-08-05 US disclosed
EP-2603502-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS Janssen Pharmaceutica, N.V. (BE) 2013-06-19 EP disclosed
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2013-06-06 US disclosed
WO-2012021830-A1 4 - AMINOQUINAZOLIN- 2 - YL - 1 - PYRRAZOLE - 4 - CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS JANSSEN PHARMACEUTICA NV (BE) 2012-02-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170320859-A1 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885
US-20180148435-A9 4-AMINOQUINAZOLIN COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885
US-20140309215-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 7/4885ADORA2A 3477/4885
US-20150197507-A1 4-Aminoquinazolinyl compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3619/4885
US-10246442-B2 4-Aminoquinazolin compounds as prolyl hydroxylase inhibitors P4HA1, EGLN3, EGLN2 EGLN1 6/4885ADORA2A 3745/4885
US-20130143871-A1 4-AMINOQUINAZOLIN-2-YL-1-PYRRAZOLE-4-CARBOXYLIC ACID COMPOUNDS AS PROLYL HYDROXYLASE INHIBITORS P4HA1, PAH, EGLN3 EGLN1 7/4885ADORA2A 3477/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.